DE60023706D1 - Diagnose und behandlung neurorektodermaler tumore - Google Patents

Diagnose und behandlung neurorektodermaler tumore

Info

Publication number
DE60023706D1
DE60023706D1 DE60023706T DE60023706T DE60023706D1 DE 60023706 D1 DE60023706 D1 DE 60023706D1 DE 60023706 T DE60023706 T DE 60023706T DE 60023706 T DE60023706 T DE 60023706T DE 60023706 D1 DE60023706 D1 DE 60023706D1
Authority
DE
Germany
Prior art keywords
treatment
neuroectodermal tumors
chlorotoxin
fusion proteins
neurorektodermaler
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60023706T
Other languages
English (en)
Other versions
DE60023706T2 (de
Inventor
J Sontheimer
A Lyons
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UAB Research Foundation
Original Assignee
UAB Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UAB Research Foundation filed Critical UAB Research Foundation
Application granted granted Critical
Publication of DE60023706D1 publication Critical patent/DE60023706D1/de
Publication of DE60023706T2 publication Critical patent/DE60023706T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
    • Y10S436/813—Cancer
DE60023706T 1999-04-21 2000-04-19 Diagnose und behandlung neurorektodermaler tumore Expired - Lifetime DE60023706T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/296,031 US6667156B2 (en) 1995-12-27 1999-04-21 Diagnosis and treatment of neuroectodermal tumors
US296031 1999-04-21
PCT/US2000/010453 WO2000062807A1 (en) 1999-04-21 2000-04-19 Diagnosis and treatment of neuroectodermal tumors

Publications (2)

Publication Number Publication Date
DE60023706D1 true DE60023706D1 (de) 2005-12-08
DE60023706T2 DE60023706T2 (de) 2006-08-03

Family

ID=23140309

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60023706T Expired - Lifetime DE60023706T2 (de) 1999-04-21 2000-04-19 Diagnose und behandlung neurorektodermaler tumore

Country Status (10)

Country Link
US (4) US6667156B2 (de)
EP (1) EP1200123B1 (de)
JP (1) JP2002542206A (de)
CN (1) CN1377280A (de)
AT (1) ATE308340T1 (de)
AU (1) AU777209B2 (de)
CA (1) CA2365533C (de)
DE (1) DE60023706T2 (de)
ES (1) ES2253223T3 (de)
WO (1) WO2000062807A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6667156B2 (en) * 1995-12-27 2003-12-23 Uab Research Foundation Diagnosis and treatment of neuroectodermal tumors
CA2494451A1 (en) * 2002-05-31 2003-12-11 Transmolecular, Inc. Treatment of cell proliferative disorders with chlorotoxin
US20060088899A1 (en) * 2002-05-31 2006-04-27 Alvarez Vernon L Combination chemotherapy with chlorotoxin
DE602006020710D1 (de) 2005-04-22 2011-04-28 Fred Hutchinson Cancer Res Foundation Fluoreszentes chlorotoxinkonjugat und verfahren zur intraoperativen sichtbarmachung von krebs
EP1934261B1 (de) * 2005-09-26 2014-10-29 Medarex, L.L.C. Humane monoklonale antikörper gegen cd70
WO2007117467A2 (en) * 2006-03-31 2007-10-18 Transmolecular, Inc. Use of tm-601 for the diagnosis and treatment of tumors
WO2008074004A2 (en) * 2006-12-14 2008-06-19 Medarex, Inc. Human antibodies that bind cd70 and uses thereof
AU2008285364A1 (en) * 2007-08-07 2009-02-12 Transmolecular, Inc. Chlorotoxins as drug carriers
WO2009049184A2 (en) * 2007-10-12 2009-04-16 Transmolecular, Inc. Systemic administration of chlorotoxin agents for the diagnosis and treatment of tumors
US8097284B2 (en) * 2007-11-13 2012-01-17 Arthur Mikaelian Polarized scorpion venom solution and a method for making polarized scorpion venom solution
CN102438646A (zh) * 2008-05-15 2012-05-02 特兰斯莫莱库拉公司 转移性肿瘤的治疗
EP2300045A1 (de) * 2008-05-15 2011-03-30 Transmolecular, Inc. Behandlung von metastatischen tumoren
KR101923235B1 (ko) 2010-02-04 2018-11-28 에이자이 아이엔씨. 클로로톡신 폴리펩티드 및 그의 접합체 및 용도
CA2799169C (en) 2010-05-11 2019-07-23 Fred Hutchinson Cancer Research Center Chlorotoxin variants, conjugates, and methods for their use
US8524239B2 (en) 2010-07-09 2013-09-03 The United States of America as represented by the Secrectary, Department of Health and Human Services Photosensitizing antibody-fluorophore conjugates
CN102552943A (zh) * 2010-12-31 2012-07-11 复旦大学 一种氯代毒素修饰的肿瘤靶向磁共振造影剂及其制备方法和应用
WO2013003507A1 (en) 2011-06-27 2013-01-03 Morphotek, Inc. Multifunctional agents
WO2014093406A1 (en) 2012-12-10 2014-06-19 Fred Hutchinson Cancer Research Center Methods for screening
US9784730B2 (en) 2013-03-21 2017-10-10 University Of Washington Through Its Center For Commercialization Nanoparticle for targeting brain tumors and delivery of O6-benzylguanine
US11559580B1 (en) 2013-09-17 2023-01-24 Blaze Bioscience, Inc. Tissue-homing peptide conjugates and methods of use thereof
JP6741599B2 (ja) 2014-06-02 2020-08-19 リ−コール，インコーポレイティド フタロシアニンプローブ及びその使用
JP6796058B2 (ja) 2014-08-08 2020-12-02 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ インビトロおよびインビボにおける標的の光制御除去
CN104877016A (zh) * 2015-04-30 2015-09-02 温州生物材料与工程研究所 折叠氯代毒素、氯代毒素变异体与折叠氯代毒素变异体及其制备工艺
US9518099B1 (en) * 2015-09-13 2016-12-13 Wenzhou Institute Of Biomaterials And Engineering Refolded chlorotoxin, chlorotoxin variant, refolded chlorotoxin variant, and preparation technology thereof
JP7409741B2 (ja) 2017-09-15 2024-01-09 エーザイ インク． クロロトキシン薬剤及びその使用
US11866466B2 (en) 2017-12-19 2024-01-09 Blaze Bioscience, Inc. Tumor homing and cell penetrating peptide-immuno-oncology agent complexes and methods of use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0282581A4 (de) * 1986-09-19 1988-11-02 Scripps Clinic Res Monoklonale paratopische moleküle, gerichtet gegen menschliches gangliosid gd2.
CA2066428C (en) 1989-09-08 2000-11-28 Bert Vogelstein Structural alterations of the egf receptor gene in human gliomas
US5223253A (en) 1989-09-28 1993-06-29 American Home Products Corporation Bovine vaccine compositions and method for preventing trichomonas infections using same
US5750376A (en) 1991-07-08 1998-05-12 Neurospheres Holdings Ltd. In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
US5626862A (en) 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
US5756340A (en) 1995-05-08 1998-05-26 The Regents Of The University Of California Insect control with multiple toxins
US6667156B2 (en) * 1995-12-27 2003-12-23 Uab Research Foundation Diagnosis and treatment of neuroectodermal tumors
US5905027A (en) * 1995-12-27 1999-05-18 Uab Research Foundation Method of diagnosing and treating gliomas
EP2300045A1 (de) * 2008-05-15 2011-03-30 Transmolecular, Inc. Behandlung von metastatischen tumoren

Also Published As

Publication number Publication date
WO2000062807A1 (en) 2000-10-26
JP2002542206A (ja) 2002-12-10
EP1200123A4 (de) 2003-05-02
EP1200123A1 (de) 2002-05-02
EP1200123B1 (de) 2005-11-02
US6667156B2 (en) 2003-12-23
US20100215576A1 (en) 2010-08-26
US7678759B2 (en) 2010-03-16
CA2365533C (en) 2012-11-06
AU4468700A (en) 2000-11-02
ES2253223T3 (es) 2006-06-01
DE60023706T2 (de) 2006-08-03
US20020146749A1 (en) 2002-10-10
ATE308340T1 (de) 2005-11-15
AU777209B2 (en) 2004-10-07
CA2365533A1 (en) 2000-10-26
US20120183544A1 (en) 2012-07-19
CN1377280A (zh) 2002-10-30
US20040141981A1 (en) 2004-07-22

Similar Documents

Publication Publication Date Title
DE60023706D1 (de) Diagnose und behandlung neurorektodermaler tumore
ATE194916T1 (de) Intraoperative, intravaskulare und endoskopische bestimmung und behandlung von verletzungen und tumoren
ZA975443B (en) Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides.
DE69731373D1 (de) Cc-chemokinzeptor c-c ckr-5, dessen derivate und verwendungen
TR199901172T2 (xx) Yeni ikame edilmi� pirazol t�revleri.
DE69921156D1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
BG103152A (en) Appoptosis-inducing adamantyl derivatives and their application as anticarcerogenic forms
ATE331534T1 (de) Anwendung von zielgerichtetem radium 223 für palliative und therapeutische behandlung von knochenkrebs
DE69631478D1 (de) Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
NO20004795D0 (no) Peptidbaserte forbindelser
DE69710490D1 (de) Triazolo(4,5-d)pyrimidinyl-derivate und ihre verwendung als medikamente
DE69622871D1 (de) Tetralin-verbindungen mit multi-drugresistenz (mdr)-aktivitat
DE29602789U1 (de) Liege, Decke o.dgl. zur therapeutischen Behandlung von Lebewesen
DE69922631D1 (de) Superkritische behandlung von aktivkohle
DE602004020266D1 (de) Therapeutische und diagnostische anti-hsp 70-antikörper
DE3783105T2 (de) Chinolinylaether tetrazole als mittel zur behandlung von hyperempfindlichen krankheiten.
DE69838509D1 (de) Verwendung von rekombinanten menschlichen uteroglobin zur behandlung von fibrotischen krankheitszuständen
WO2002081745A3 (en) Genes involved in osteogenesis, and methods of use
MXPA00010254A (es) Tratamiento de disfuncion sexual en ciertos grupos de pacientes.
DE69924979D1 (de) Behandlung von chronischen schmerzen
EA200000909A1 (ru) ФОРМА VI 5,6-ДИХЛОР-2-(ИЗОПРОПИЛАМИНО)-1-(b-L-РИБОФУРАНОЗИЛ)-1H-БЕНЗИМИДАЗОЛА
BR9811402A (pt) Uso topicamente ou em outro modo administrado, de endipalene em qualquer concentração e em qualquer solvente
FI913531A0 (fi) Anvaendning av 1,2-bensopyronderivater till behandling av maligna tumoerer hos maenniskan.
NO984965D0 (no) Komponent B som cicatrisant
WO2004024877A3 (en) Human kininogen d3 domain polypeptide as an anti-angiogenic and anti-tumor agent

Legal Events

Date Code Title Description
8364 No opposition during term of opposition